Targeting the follicular lymphoma microenvironment
Towards targeting the lymphoma microenvironment
This project aims to find ways to disrupt the supportive tissue around follicular lymphoma cells so treatments work better for people with follicular lymphoma.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11169712 on NIH RePORTER |
What this research studies
Follicular lymphoma is a slow-growing B-cell cancer that depends on nearby normal and immune cells for survival. Researchers use genetic studies and accurate mouse models along with analysis of tumor samples to learn how cell-to-cell interactions protect the cancer and cause resistance to therapy. The team will test strategies to break those protective interactions to make drugs like PI3K, BTK, or BCL2 inhibitors more effective against indolent FL. Findings will guide new therapeutic approaches and possible clinical translation.
Who could benefit from this research
Good fit: People with follicular lymphoma — especially those with indolent disease or who have relapsed after standard therapies, or patients willing to provide biopsy or blood samples — would be most relevant to this work.
Not a fit: Patients with aggressive non-follicular lymphomas or anyone seeking an immediate approved treatment benefit are unlikely to gain direct benefit from this preclinical-focused project.
Why it matters
Potential benefit: If successful, this work could make existing targeted treatments work better for people with follicular lymphoma and reduce treatment resistance.
How similar studies have performed: Targeted drugs like BTK, PI3K, and BCL2 inhibitors work in other lymphomas, but approaches specifically aimed at disrupting the follicular lymphoma microenvironment are still early and mainly preclinical.
Where this research is happening
New York, United States
- Sloan-Kettering Inst Can Research — New York, United States (Active)
Researchers
- Principal investigator: Wendel, Hans-Guido — Sloan-Kettering Inst Can Research
- Study coordinator: Wendel, Hans-Guido
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.